Lifevantage (LFVN) Cash & Equivalents (2010 - 2026)

Lifevantage has reported Cash & Equivalents for 17 years, with the latest figure at $12.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 44.44% year-over-year to $12.5 million; the trailing twelve-month figure through Mar 2026 stood at $12.5 million (down 44.44% YoY), and the FY2025 full-year result was $20.2 million, up 19.63% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $12.5 million, up from $10.2 million in the prior quarter.
• The five-year high for Cash & Equivalents was $22.5 million in Q1 2025, with the low at $10.2 million in Q4 2025.
• Historically, Cash & Equivalents has averaged $17.6 million across 5 years, with a median of $17.6 million in 2022.
• The largest YoY upside for Cash & Equivalents was 29.3% in 2025 against a maximum downside of 52.85% in 2025.
• Lifevantage's Cash & Equivalents stood at $17.4 million in 2022, then fell by 0.22% to $17.3 million in 2023, then climbed by 24.6% to $21.6 million in 2024, then sank by 52.85% to $10.2 million in 2025, then increased by 22.61% to $12.5 million in 2026.
• The last three Cash & Equivalents figures came in at $12.5 million (Q1 2026), $10.2 million (Q4 2025), and $13.1 million (Q3 2025), per Business Quant data.